S&T Bank’s Supernus Pharmaceuticals SUPN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $2.04M | Sell |
43,888
-8,597
| -16% | -$413K | 0.61% | 34 |
|
|
2026
Q1 | $2.71M | Sell |
52,485
-22,639
| -30% | -$1.15M | 1.01% | 30 |
|
|
2025
Q4 | $3.73M | Sell |
75,124
-13,791
| -16% | -$671K | 1.18% | 29 |
|
|
2025
Q3 | $4.25M | Sell |
88,915
-18,506
| -17% | -$745K | 1.19% | 34 |
|
|
2025
Q2 | $3.39M | Sell |
107,421
-3,656
| -3% | -$117K | 1.03% | 38 |
|
|
2025
Q1 | $3.64M | Sell |
111,077
-1,110
| -1% | -$39.3K | 1.19% | 33 |
|
|
2024
Q4 | $4.06M | Sell |
112,187
-11,146
| -9% | -$392K | 1.29% | 34 |
|
|
2024
Q3 | $3.85M | Sell |
123,333
-4,303
| -3% | -$134K | 1.01% | 41 |
|
|
2024
Q2 | $3.41M | Sell |
127,636
-47,928
| -27% | -$1.39M | 0.87% | 48 |
|
|
2024
Q1 | $5.99M | Sell |
175,564
-13,792
| -7% | -$411K | 1.15% | 42 |
|
|
2023
Q4 | $5.48M | Sell |
189,356
-26,222
| -12% | -$695K | 1.01% | 44 |
|
|
2023
Q3 | $5.94M | Sell |
215,578
-5,665
| -3% | -$172K | 1.15% | 41 |
|
|
2023
Q2 | $6.65M | Sell |
221,243
-2,532
| -1% | -$88.6K | 1.2% | 41 |
|
|
2023
Q1 | $8.11M | Sell |
223,775
-65,494
| -23% | -$2.52M | 1.46% | 34 |
|
|
2022
Q4 | $10.3M | Sell |
289,269
-11,957
| -4% | -$416K | 1.9% | 16 |
|
|
2022
Q3 | $10.2M | Sell |
301,226
-12,164
| -4% | -$396K | 1.97% | 16 |
|
|
2022
Q2 | $9.06M | Sell |
313,390
-2,936
| -0.9% | -$84.1K | 1.59% | 25 |
|
|
2022
Q1 | $10.2M | Sell |
316,326
-243
| -0.1% | -$7.45K | 1.54% | 26 |
|
|
2021
Q4 | $9.23M | Buy |
316,569
+471
| +0.1% | +$14.3K | 1.35% | 32 |
|
|
2021
Q3 | $8.43M | Sell |
316,098
-2,584
| -0.8% | -$69.4K | 1.31% | 34 |
|
|
2021
Q2 | $9.81M | Sell |
318,682
-851
| -0.3% | -$26.1K | 1.52% | 26 |
|
|
2021
Q1 | $8.37M | Sell |
319,533
-611
| -0.2% | -$17.1K | 1.36% | 31 |
|
|
2020
Q4 | $8.05M | Buy |
320,144
+406
| +0.1% | +$8.74K | 1.45% | 33 |
|
|
2020
Q3 | $6.66M | Buy |
319,738
+18,852
| +6% | +$428K | 1.52% | 30 |
|
|
2020
Q2 | $7.15M | Sell |
300,886
-4,628
| -2% | -$102K | 1.63% | 28 |
|
|
2020
Q1 | $5.5M | Buy |
305,514
+51,659
| +20% | +$1.09M | 1.51% | 29 |
|
|
2019
Q4 | $6.02M | Buy |
253,855
+1,532
| +0.6% | +$37.2K | 1.23% | 37 |
|
|
2019
Q3 | $6.94M | Buy |
252,323
+9,764
| +4% | +$289K | 1.5% | 32 |
|
|
2019
Q2 | $8.03M | Buy |
242,559
+79,525
| +49% | +$2.72M | 1.76% | 23 |
|
|
2019
Q1 | $5.71M | Buy |
+163,034
| New | +$6.07M | 1.29% | 39 |
|
Other funds holding SUPN
AC
NAMI
SIMG
S&T Bank's SUPN Position: Q2 2026 in Review
S&T Bank reduced its Supernus Pharmaceuticals (SUPN) stake by 16% in Q2 2026, selling an estimated $413K and leaving 43,888 shares worth $2.04M. The position accounts for 0.61% of the portfolio, ranked #34.
S&T Bank first reported a position in SUPN in Q1 2019 and has held it in 30 quarters since. The position peaked at $10.3M in Q4 2022. 335 funds tracked by Wall St. Rank hold SUPN as of Q2 2026.
- S&T Bank held 43,888 shares of Supernus Pharmaceuticals worth $2.04M as of Q2 2026.
- S&T Bank sold 8,597 Supernus Pharmaceuticals shares in Q2 2026, an estimated $413K.
- Supernus Pharmaceuticals made up 0.61% of S&T Bank's portfolio in Q2 2026, its #34 holding.
- S&T Bank first reported a position in Supernus Pharmaceuticals in Q1 2019 and has held it in 30 quarters since.
- S&T Bank's Supernus Pharmaceuticals position peaked at $10.3M in Q4 2022.
- 335 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2026.
Based on S&T Bank's 13F filing for Q2 2026, filed 12 Aug 2026.